CY2014004I2 - Χρηση (ζ)-2-κυανο-3-υδροξυ-βουτ-2-ενοικου οξεος-(4΄-τριφθορομεθυλοφαινυλο)-αμιδης για τη θεραπεια της πολλαπλης σκληρωσης - Google Patents

Χρηση (ζ)-2-κυανο-3-υδροξυ-βουτ-2-ενοικου οξεος-(4΄-τριφθορομεθυλοφαινυλο)-αμιδης για τη θεραπεια της πολλαπλης σκληρωσης

Info

Publication number
CY2014004I2
CY2014004I2 CY2014004C CY2014004C CY2014004I2 CY 2014004 I2 CY2014004 I2 CY 2014004I2 CY 2014004 C CY2014004 C CY 2014004C CY 2014004 C CY2014004 C CY 2014004C CY 2014004 I2 CY2014004 I2 CY 2014004I2
Authority
CY
Cyprus
Prior art keywords
trifluoromethylphenyl
cyano
amide
hydroxy
treatment
Prior art date
Application number
CY2014004C
Other languages
Greek (el)
English (en)
Other versions
CY2014004I1 (el
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26246599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2014004(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0123571.2A external-priority patent/GB0123571D0/en
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of CY2014004I1 publication Critical patent/CY2014004I1/el
Publication of CY2014004I2 publication Critical patent/CY2014004I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY2014004C 2001-04-05 2014-01-23 Χρηση (ζ)-2-κυανο-3-υδροξυ-βουτ-2-ενοικου οξεος-(4΄-τριφθορομεθυλοφαινυλο)-αμιδης για τη θεραπεια της πολλαπλης σκληρωσης CY2014004I2 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28168501P 2001-04-05 2001-04-05
GBGB0123571.2A GB0123571D0 (en) 2001-04-05 2001-10-02 Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
PCT/US2002/010773 WO2002080897A1 (en) 2001-04-05 2002-04-04 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis

Publications (2)

Publication Number Publication Date
CY2014004I1 CY2014004I1 (el) 2015-12-09
CY2014004I2 true CY2014004I2 (el) 2015-12-09

Family

ID=26246599

Family Applications (1)

Application Number Title Priority Date Filing Date
CY2014004C CY2014004I2 (el) 2001-04-05 2014-01-23 Χρηση (ζ)-2-κυανο-3-υδροξυ-βουτ-2-ενοικου οξεος-(4΄-τριφθορομεθυλοφαινυλο)-αμιδης για τη θεραπεια της πολλαπλης σκληρωσης

Country Status (15)

Country Link
EP (2) EP1935416A3 (OSRAM)
AR (1) AR033459A1 (OSRAM)
AT (1) ATE396719T1 (OSRAM)
CA (1) CA2443285C (OSRAM)
CY (1) CY2014004I2 (OSRAM)
DE (1) DE60226855D1 (OSRAM)
DK (1) DK1381356T3 (OSRAM)
ES (1) ES2305287T3 (OSRAM)
FR (1) FR14C0010I2 (OSRAM)
LU (1) LU92366I2 (OSRAM)
PA (1) PA8542901A1 (OSRAM)
PT (1) PT1381356E (OSRAM)
SI (1) SI1381356T1 (OSRAM)
UY (1) UY27244A1 (OSRAM)
WO (1) WO2002080897A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003293500A1 (en) 2002-12-12 2004-07-09 Agennix Incorporated Lactoferrin in the reduction of pain
CN101043883A (zh) * 2004-10-19 2007-09-26 安万特药物公司 (z)－2－氰基－3－羟基－丁－2－烯酸－(4'－三氟甲基苯基)－酰胺用于治疗炎症性肠病的用途
JP5021488B2 (ja) 2004-12-21 2012-09-05 メルク セローノ ソシエテ アノニム スルホニルアミノ環式誘導体及びその使用
KR20070105326A (ko) 2005-01-31 2007-10-30 라보라뚜와르 세로노 에스. 에이. Ｎ-하이드록시아미드 유도체 및 그것의 용도
CN101282740A (zh) 2005-09-01 2008-10-08 阿雷斯贸易股份有限公司 视神经炎的治疗
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
EP2100881A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Pyrimidyl- or pyridinylaminobenzoic acid derivatives
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2277515A1 (en) * 2009-07-10 2011-01-26 Sanofi-Aventis Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
DK2477611T3 (en) 2009-09-18 2017-07-10 Sanofi Sa (Z) -2-CYANO-3-HYDROXYBUT-2-ENIC ACID (4'-TRIFLUORMETHYLPHENYL) AMID TABLE FORMULATIONS WITH IMPROVED STABILITY
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
EP2672963A4 (en) 2011-02-08 2015-06-24 Childrens Medical Center METHOD FOR THE TREATMENT OF MELANOMA
EP2762135A1 (en) * 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
WO2016189406A1 (en) 2015-05-23 2016-12-01 Ftf Pharma Private Limited Pharmaceutical composition of teriflunomide
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
GR1010137B (el) 2020-12-15 2021-12-07 Φαρματεν Α.Β.Ε.Ε., Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL178596C (nl) 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
TW314467B (OSRAM) 1993-03-31 1997-09-01 Hoechst Ag
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate

Also Published As

Publication number Publication date
CA2443285A1 (en) 2002-10-17
CY2014004I1 (el) 2015-12-09
PA8542901A1 (es) 2003-11-12
DE60226855D1 (de) 2008-07-10
LU92366I2 (fr) 2014-03-31
EP1935416A3 (en) 2008-10-22
EP1381356A1 (en) 2004-01-21
DK1381356T3 (da) 2008-09-22
ES2305287T3 (es) 2008-11-01
PT1381356E (pt) 2008-07-24
WO2002080897A1 (en) 2002-10-17
UY27244A1 (es) 2002-07-31
SI1381356T1 (sl) 2008-12-31
EP1935416A2 (en) 2008-06-25
CA2443285C (en) 2007-08-21
FR14C0010I2 (fr) 2014-11-21
FR14C0010I1 (OSRAM) 2014-03-14
EP1381356B1 (en) 2008-05-28
AR033459A1 (es) 2003-12-17
ATE396719T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
CY2014004I2 (el) Χρηση (ζ)-2-κυανο-3-υδροξυ-βουτ-2-ενοικου οξεος-(4΄-τριφθορομεθυλοφαινυλο)-αμιδης για τη θεραπεια της πολλαπλης σκληρωσης
CY2009013I2 (el) Νεα χρηση μιας ενωσης πεπτιδικης κατηγοριας για τη θεραπεια του μη νευροπαθους φλεγμονωδους πονου
CY2016043I2 (el) Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης
EP1383528A4 (en) EPITOPE SEQUENCES
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
EP1424946A4 (en) BONE PLATES
NO20052474D0 (no) Amort form av esomeprazolsalter
EE200400042A (et) 8/17 heterotsüklilised ühendid ning nende kasutamine D-alanüül-D-alaniini ligaasi inhibiitoritena
DE60204155D1 (de) Filmmaterial
GB0123571D0 (en) Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
EP1591399A4 (en) LIFT DEVICE
DE60217089D1 (de) Lipidsenkende biphenylcarbonsäureamide
NO20035380D0 (no) Fremgangsmåte for dannelse av m degree nster
PT1429926E (pt) Circuito de interligacao
DE60206333D1 (de) Kopfdichtung
NO20025964L (no) Ny interferon for behandling av multippel sklerose
EP1602614A4 (en) LIFT EQUIPMENT
FI20011507A0 (fi) Uusia yhdisteitä
EP1564177A4 (en) LIFT FACILITY
NO20042613L (no) Ny anvendelse for behandling av gastroosofagial refluks
DE60228126D1 (de) Hochtemperaturbeständiges klebeband
DE60214475D1 (de) Reinigungsband
ITMI20021739A1 (it) Procedimento ed apparecchiatura per la produzione di
DE60217482D1 (de) Reinigungseinrichtung
EP1571113A4 (en) LIFT FACILITY